Literature DB >> 21635237

Anomalous levels of Cl- transporters cause a decrease of GABAergic inhibition in human peritumoral epileptic cortex.

Luca Conti1, Eleonora Palma, Cristina Roseti, Clotilde Lauro, Raffaela Cipriani, Marjolein de Groot, Eleonora Aronica, Cristina Limatola.   

Abstract

PURPOSE: Several factors contribute to epileptogenesis in patients with brain tumors, including reduced γ-aminobutyric acid (GABA)ergic inhibition. In particular, changes in Cl(-) homeostasis in peritumoral microenvironment, together with alterations of metabolism, are key processes leading to epileptogenesis in patients afflicted by glioma. It has been recently proposed that alterations of Cl(-) homeostasis could be involved in tumor cell migration and metastasis formation. In neurons, the regulation of intracellular Cl(-) concentration ([Cl(-) ](i) ) is mediated by NKCC1 and KCC2 transporters: NKCC1 increases while KCC2 decreases [Cl(-) ](i) . Experiments were thus designed to investigate whether, in human epileptic peritumoral cortex, alterations in the balance of NKCC1 and KCC2 activity may decrease the hyperpolarizing effects of GABA, thereby contributing to epileptogenesis in human brain tumors.
METHODS: Membranes from peritumoral cortical tissues of epileptic patients afflicted by gliomas (from II to IV WHO grade) and from cortical tissues of nonepileptic patients were injected into Xenopus oocytes leading to the incorporation of functional GABA(A) receptors. The GABA-evoked currents were recorded using standard two-microelectrode voltage-clamp technique. In addition, immunoblot analysis and immunohistochemical staining were carried out on membranes and tissues from the same patients. KEY
FINDINGS: We found that in oocytes injected with epileptic peritumoral cerebral cortex, the GABA-evoked currents had a more depolarized reversal potential (E(GABA) ) compared to those from nonepileptic healthy cortex. This difference of E(GABA) was abolished by the NKCC1 blocker bumetanide or unblocking of KCC2 with the Zn(2+) chelator TPEN. Moreover, Western blot analysis revealed an increased expression of NKCC1, and more modestly, of KCC2 transporters in epileptic peritumoral tissues compared to nonepileptic control tissues. In addition, NKCC1 immunoreactivity was strongly increased in peritumoral cortex with respect to nonepileptic cortex, with a prominent expression in neuronal cells. SIGNIFICANCE: We report that the positive shift of E(GABA) in epileptic peritumoral human cortex is due to an altered expression of NKCC1 and KCC2, perturbing Cl(-) homeostasis, which might lead to a consequent reduction in GABAergic inhibition. These findings point to a key role of Cl(-) transporters KCC2 and NKCC1 in tumor-related epilepsy, suggesting a more specific drug therapy and surgical approaches for the epileptic patients afflicted by brain tumors. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21635237     DOI: 10.1111/j.1528-1167.2011.03111.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  28 in total

1.  GABAergic disinhibition and impaired KCC2 cotransporter activity underlie tumor-associated epilepsy.

Authors:  Susan L Campbell; Stefanie Robel; Vishnu A Cuddapah; Stephanie Robert; Susan C Buckingham; Kristopher T Kahle; Harald Sontheimer
Journal:  Glia       Date:  2014-07-26       Impact factor: 7.452

Review 2.  Novel treatment targets for cerebral edema.

Authors:  Brian P Walcott; Kristopher T Kahle; J Marc Simard
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 3.  Epilepsy related to developmental tumors and malformations of cortical development.

Authors:  Eleonora Aronica; Peter B Crino
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 4.  Seizures and gliomas--towards a single therapeutic approach.

Authors:  Gilles Huberfeld; Charles J Vecht
Journal:  Nat Rev Neurol       Date:  2016-03-11       Impact factor: 42.937

Review 5.  WONOEP appraisal: Development of epilepsy biomarkers-What we can learn from our patients?

Authors:  Sergiusz Jozwiak; Albert Becker; Carlos Cepeda; Jerome Engel; Vadym Gnatkovsky; Gilles Huberfeld; Mehmet Kaya; Katja Kobow; Michele Simonato; Jeffrey A Loeb
Journal:  Epilepsia       Date:  2017-04-07       Impact factor: 5.864

6.  Sevoflurane-based enhancement of phase-amplitude coupling and localization of the epileptogenic zone.

Authors:  Keiko Wada; Masaki Sonoda; Ethan Firestone; Kazuki Sakakura; Naoto Kuroda; Yutaro Takayama; Keiya Iijima; Masaki Iwasaki; Takahiro Mihara; Takahisa Goto; Eishi Asano; Tomoyuki Miyazaki
Journal:  Clin Neurophysiol       Date:  2021-12-01       Impact factor: 3.708

Review 7.  Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy.

Authors:  Terri S Armstrong; Robin Grant; Mark R Gilbert; Jong Woo Lee; Andrew D Norden
Journal:  Neuro Oncol       Date:  2015-11-02       Impact factor: 12.300

8.  Compromised GABAergic inhibition contributes to tumor-associated epilepsy.

Authors:  Georgina MacKenzie; Kate K O'Toole; Stephen J Moss; Jamie Maguire
Journal:  Epilepsy Res       Date:  2016-07-27       Impact factor: 3.045

9.  Cortical GABAergic excitation contributes to epileptic activities around human glioma.

Authors:  Michel Le Van Quyen; Franck Bielle; Christophe Pellegrino; Johan Pallud; Pascale Varlet; Noemie Cresto; Michel Baulac; Charles Duyckaerts; Nazim Kourdougli; Geneviève Chazal; Bertrand Devaux; Claudio Rivera; Richard Miles; Laurent Capelle; Gilles Huberfeld
Journal:  Sci Transl Med       Date:  2014-07-09       Impact factor: 17.956

10.  Transient increase in neuronal chloride concentration by neuroactive aminoacids released from glioma cells.

Authors:  Cristina Bertollini; Emanuele Murana; Luciana Mosca; Maria D'Erme; Federico Scala; Antonio Francioso; Myriam Catalano; Cristina Limatola; Piotr Bregestovski; Silvia Di Angelantonio; Davide Ragozzino
Journal:  Front Mol Neurosci       Date:  2012-11-26       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.